Clinical Trial Update: Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults [Phase 2]

View source ↗

Summary

Phase 2 trial assessing Ombitasvir/Paritaprevir/ritonavir plus Dasabuvir with low-dose, full-dose, or add-on ribavirin in treatment-naive genotype 1a hepatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Dasabuvir (dasabuvir)
• Ombitasvir (ombitasvir)
• Paritaprevir (ABT-450) (Paritaprevir)
• Ribavirin (ribavirin)
• Ritonavir (Ritonavir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C, Hepatitis C (HCV) | Phase 2 | Status: COMPLETED | Results posted: 2017-05-15